The big pharma could not confirm whether AveXis co-founder and CSO Brian Kaspar and his brother, SVP of R&D Allan Kaspar, were fired. Instead, Novartis noted that the withholding of preclinical safety data for Zolgensma was limited to the action of a few employees. NIBR preclinical safety chief takes key role at AveXis

With its first AAV gene therapy candidate from Bamboo Therapeutics expected to report data in 2019, Pfizer’s efforts to get in the DMD competition now center on that modality.

Brief profiles of these recently formed companies: Abionic, Alcresta, Avenir Medical and Milo Biotechnology.

Brief profiles of these recently formed companies: Abionic, Alcresta, Avenir Medical, Avion Pharmaceuticals, Ground Fluor Pharmaceuticals and Milo Biotechnology.